A.D.A.M. develops an on-demand personalized implant manufacturing infrastructure with a full scope of related services, provided remotely or on site
A.D.A.M. was founded in 2018 by 3D printing company Kwambio and WeFund Ventures in Ukraine. The initial vision of the company was to create a carshop-like infrastructure where any part of the human body can be treated like a replaceable part. A.D.A.M. team decided to start the development of the project with a focus on bone implants and have developed proprietary 3D printing technology and material composites for the implants. The first prototypes passed pre-clinical trials in wistar rats. Successful results of the trials allowed A.D.A.M. to file the Q-Submission to the FDA. In their response, the FDA confirmed A.D.A.M. biopolymer and bioceramic bone implants' 510(k) eligibility. Concurrently, the company moved its HQs to the Technology Incubation Program at University of Connecticut.
The company had its first two PCT patents published in 2021. A.D.A.M. is also proud to have been accepted to Elementa Labs, an incubation program of Mount Sinai Innovation Partners.
A.D.A.M. plans to complete the animal studies, required by the FDA, in 2023. Next, the company aims to receive regulatory clearance for bone implants and begin the sales stage in 2024.
Bone implants are just the beginning - in the years to come A.D.A.M. aims to launch R&D of blood vessel, heart valve and bronchial implants.
TEAM
MANAGEMENT TEAM
ADVISORY BOARD
R&D TEAM
PRESS RELEASES
PARTNERS
Long-established bioscience ecosystem
Technology Incubation Program at the University of Connecticut
Early-stage venture capital firm
Top-Tier law firm in the area of "FDA Law"
MSIP translates Mount Sinai discoveries and innovations into commercial healthcare products
Fortune 500 American manufacturer of industrial tools and household hardware
One of the biggest network of seed accelerators in US
Top 3D-printing company
Industry oriented center dedicated to pre-competitive research in additive manufacturing